Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Malathion is a parasympathomimetic organophosphate compound primarily used as an insecticide and pediculicide. In medicine, it is approved as a topical lotion for the treatment of head lice in adults and children aged 6 years and older. Malathion acts as an irreversible inhibitor of acetylcholinesterase (AChE), leading to accumulation of acetylcholine at nerve endings and disruption of normal nerve signal transmission in insects. Its principal toxicological effect is cholinesterase inhibition due to its active metabolite malaoxon. Malathion has relatively low toxicity in humans compared to insects because mammals metabolize it more rapidly into non-toxic products[1][2][3][4][5][7]. It is also widely used as an agricultural insecticide for controlling mosquitoes, fruit flies, fleas on pets, and other pests[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on malathion.